Physician profile
John Randolph Forehand
NPI 1902888258
$1,261.54
in general payments reported to CMS, 2019-2025
14 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $209 · 2021: $273 · 2022: $101 · 2023: $266 · 2024: $149 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.54 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.77 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $272.91 | 2021-2024 | Trelegy Ellipta, Nucala |
| Sunovion Pharmaceuticals INC. | $223.03 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2024 | Dupixent |
| Mylan Specialty L.P. | $41.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.38 | 2019-2021 | |
| Optinose US, INC. | $21.06 | 2020 | |
| Corcept Therapeutics | $18.67 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $17.59 | 2025 | |
| Insmed, INC. | $16.24 | 2023 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2022 | |
| Merck Sharp & Dohme LLC | $13.57 | 2024 | Vaxneuvance, Gardasil, Capvaxive |
| Alkermes, INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Forehand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.